 |
Doug Macron is the editor of GenomeWeb's Gene Silencing News. He covers research and therapeutic applications of RNAi, miRNA, and other gene-silencing technologies. E-mail Doug Macron or follow his GenomeWeb Twitter account at @Genesilencing. |
Genable Secures License to Benitec RNAi Technology as It Eyes Rare Ocular Disease
July 19, 2012
Genable Secures License to Benitec RNAi Technology as It Eyes Rare Ocular Disease
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Genable Receives FDA Orphan Drug Status for Ocular Disease Drug
April 18, 2013 / Gene Silencing News - Mass. Court Dismisses CSHL Lawsuit Against Former IP Counsel
March 21, 2013 / Gene Silencing News - University of Amsterdam Team Identifies Argonaute as Key to Dicer-Independent shRNA Processing
February 14, 2013 / Gene Silencing News - UniQure Enters RNAi Field with Benitec Cross-Licensing Deal
December 6, 2012 / Gene Silencing News - Benitec Announces Positive In Vitro Data from Muscular Dystrophy Program
December 6, 2012 / Gene Silencing News